Therapeutic potential of targeting the oncogenic SHP2 phosphatase

Li Fan Zeng, Ruo Yu Zhang, Zhi Hong Yu, Sijiu Li, Li Wu, Andrea M. Gunawan, Brandon S. Lane, Raghuveer S. Mali, Xingjun Li, Rebecca Chan, Reuben Kapur, Clark Wells, Zhong-Yin Zhang

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase associated with various kinds of leukemia and solid tumors. Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents. Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor 11a-1, with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs. Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5- β6 loop contribute to 11a-1's binding potency and selectivity. Evidence suggests that 11a-1 specifically attenuates the SHP2-dependent signaling inside the cell. Moreover, 11a-1 blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.

Original languageEnglish
Pages (from-to)6594-6609
Number of pages16
JournalJournal of Medicinal Chemistry
Volume57
Issue number15
DOIs
StatePublished - Aug 14 2014

Fingerprint

Non-Receptor Type 11 Protein Tyrosine Phosphatase
Carboxylic Acids
Leukemia
SH2 Domain-Containing Protein Tyrosine Phosphatases
Breast Neoplasms
Protein Phosphatase 2
Protein Tyrosine Phosphatases
Phosphoric Monoester Hydrolases
Antineoplastic Agents
Inhibitory Concentration 50
Libraries
Lung Neoplasms
Catalytic Domain
Intercellular Signaling Peptides and Proteins
Cell Line
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Medicine(all)

Cite this

Zeng, L. F., Zhang, R. Y., Yu, Z. H., Li, S., Wu, L., Gunawan, A. M., ... Zhang, Z-Y. (2014). Therapeutic potential of targeting the oncogenic SHP2 phosphatase. Journal of Medicinal Chemistry, 57(15), 6594-6609. https://doi.org/10.1021/jm5006176

Therapeutic potential of targeting the oncogenic SHP2 phosphatase. / Zeng, Li Fan; Zhang, Ruo Yu; Yu, Zhi Hong; Li, Sijiu; Wu, Li; Gunawan, Andrea M.; Lane, Brandon S.; Mali, Raghuveer S.; Li, Xingjun; Chan, Rebecca; Kapur, Reuben; Wells, Clark; Zhang, Zhong-Yin.

In: Journal of Medicinal Chemistry, Vol. 57, No. 15, 14.08.2014, p. 6594-6609.

Research output: Contribution to journalArticle

Zeng, LF, Zhang, RY, Yu, ZH, Li, S, Wu, L, Gunawan, AM, Lane, BS, Mali, RS, Li, X, Chan, R, Kapur, R, Wells, C & Zhang, Z-Y 2014, 'Therapeutic potential of targeting the oncogenic SHP2 phosphatase', Journal of Medicinal Chemistry, vol. 57, no. 15, pp. 6594-6609. https://doi.org/10.1021/jm5006176
Zeng LF, Zhang RY, Yu ZH, Li S, Wu L, Gunawan AM et al. Therapeutic potential of targeting the oncogenic SHP2 phosphatase. Journal of Medicinal Chemistry. 2014 Aug 14;57(15):6594-6609. https://doi.org/10.1021/jm5006176
Zeng, Li Fan ; Zhang, Ruo Yu ; Yu, Zhi Hong ; Li, Sijiu ; Wu, Li ; Gunawan, Andrea M. ; Lane, Brandon S. ; Mali, Raghuveer S. ; Li, Xingjun ; Chan, Rebecca ; Kapur, Reuben ; Wells, Clark ; Zhang, Zhong-Yin. / Therapeutic potential of targeting the oncogenic SHP2 phosphatase. In: Journal of Medicinal Chemistry. 2014 ; Vol. 57, No. 15. pp. 6594-6609.
@article{2f955231b25a4666871d23722c8d2c9f,
title = "Therapeutic potential of targeting the oncogenic SHP2 phosphatase",
abstract = "The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase associated with various kinds of leukemia and solid tumors. Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents. Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor 11a-1, with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs. Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5- β6 loop contribute to 11a-1's binding potency and selectivity. Evidence suggests that 11a-1 specifically attenuates the SHP2-dependent signaling inside the cell. Moreover, 11a-1 blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.",
author = "Zeng, {Li Fan} and Zhang, {Ruo Yu} and Yu, {Zhi Hong} and Sijiu Li and Li Wu and Gunawan, {Andrea M.} and Lane, {Brandon S.} and Mali, {Raghuveer S.} and Xingjun Li and Rebecca Chan and Reuben Kapur and Clark Wells and Zhong-Yin Zhang",
year = "2014",
month = "8",
day = "14",
doi = "10.1021/jm5006176",
language = "English",
volume = "57",
pages = "6594--6609",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "15",

}

TY - JOUR

T1 - Therapeutic potential of targeting the oncogenic SHP2 phosphatase

AU - Zeng, Li Fan

AU - Zhang, Ruo Yu

AU - Yu, Zhi Hong

AU - Li, Sijiu

AU - Wu, Li

AU - Gunawan, Andrea M.

AU - Lane, Brandon S.

AU - Mali, Raghuveer S.

AU - Li, Xingjun

AU - Chan, Rebecca

AU - Kapur, Reuben

AU - Wells, Clark

AU - Zhang, Zhong-Yin

PY - 2014/8/14

Y1 - 2014/8/14

N2 - The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase associated with various kinds of leukemia and solid tumors. Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents. Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor 11a-1, with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs. Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5- β6 loop contribute to 11a-1's binding potency and selectivity. Evidence suggests that 11a-1 specifically attenuates the SHP2-dependent signaling inside the cell. Moreover, 11a-1 blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.

AB - The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase associated with various kinds of leukemia and solid tumors. Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents. Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor 11a-1, with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs. Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5- β6 loop contribute to 11a-1's binding potency and selectivity. Evidence suggests that 11a-1 specifically attenuates the SHP2-dependent signaling inside the cell. Moreover, 11a-1 blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.

UR - http://www.scopus.com/inward/record.url?scp=84906080682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906080682&partnerID=8YFLogxK

U2 - 10.1021/jm5006176

DO - 10.1021/jm5006176

M3 - Article

C2 - 25003231

AN - SCOPUS:84906080682

VL - 57

SP - 6594

EP - 6609

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 15

ER -